ZimVie Stockholders Approve Acquisition by ARCHIMED, Merger Expected to Close October 20.

ZimVie Inc. stockholders have approved the acquisition by ARCHIMED, with the merger expected to close on October 20, 2025. ZimVie is a global life sciences leader in the dental implant market, with a portfolio of products and solutions to support dental care. The acquisition is part of ARCHIMED's strategy to expand its presence in the healthcare industry.

ZimVie Inc. (ZIMV), a global life sciences leader in the dental implant market, has received shareholder approval for its acquisition by an affiliate of ARCHIMED, a private equity firm. The approval follows a merger agreement signed on July 20, 2025, under which ZimVie will be acquired for $19 per share in cash. The acquisition is expected to close on October 20, 2025.

ZimVie's stock closed at $18.97 on Thursday, September 12, 2025, up 0.21% from the previous close. The company's acquisition by ARCHIMED is part of the private equity firm's strategy to expand its presence in the healthcare industry. ARCHIMED's affiliate will pay $19 per share, a 0.3% premium over the closing price on Thursday.

The acquisition is expected to provide ZimVie with significant financial resources to further develop its product portfolio and expand its market reach. ZimVie's dental implant solutions are used worldwide, and the company has a strong reputation for innovation and quality.

The approval of the acquisition by ZimVie's shareholders is a significant step forward in the company's history. The transaction is subject to certain conditions, including regulatory approvals and the satisfaction of other customary closing conditions. The expected closing date is October 20, 2025.

For more information on the acquisition and ZimVie's financial performance, visit the company's investor relations website.

Reference List:
ZimVie Shareholders Approve Acquisition By ARCHIMED Affiliate^[1] https://www.nasdaq.com/articles/zimvie-shareholders-approve-acquisition-archimed-affiliate
Aardvark Announces Expansion Of Phase 3 HERO Trial Of ARD-101^[2] https://www.nasdaq.com/articles/aardvark-announces-expansion-phase-3-hero-trial-ard-101